Vertex Pharmaceuticals (VRTX) stock has performed strongly since the turn of the year, gaining 14.6% and vastly outperforming ...

Vertex Pharmaceuticals (NASDAQ: VRTX) just snagged its second U.S. Food and Drug Administration (FDA) approval in only 41 ...

Lately, one of America's leading pharmaceutical companies can't catch a break from Wall Street. Shares of Vertex ...

A non-opioid pain medication made by Vertex Pharmaceuticals has received approval for adults from the Food and Drug ...

Will people with acute pain want a new painkiller whose list price is $15.50 a pill when a generic prescription drug is at ...

Shares of Vertex Pharmaceuticals Inc. surged ahead of Friday’s market open after the Food and Drug Administration approved ...

Shares of Vertex Pharmaceuticals rose after Journavx, the company’s oral non-opioid pain medication, received Food and Drug ...

Analyst is bullish on Vertex Pharmaceuticals, citing FDA approval for JOURNAVX and strong earnings growth potential in 2025.

The U.S. Food and Drug Administration has approved Vertex Pharmaceuticals' drug to treat acute pain, the health regulator ...

Analyst Salveen Richter of Goldman Sachs maintained a Buy rating on Vertex Pharmaceuticals (VRTX – Research Report), reducing the price target ...

Precision medicine is revolutionizing healthcare, and these genomic stocks are leading the way. Therefore, as this sector ...

The bottom line is few companies can match its combination of established leadership in rare diseases and realistic pathways ...